Mutual of America Capital Management LLC Acquires 2,689 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Mutual of America Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 2.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 132,978 shares of the company’s stock after purchasing an additional 2,689 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.32% of Tarsus Pharmaceuticals worth $5,387,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TARS. Amalgamated Bank increased its holdings in shares of Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock worth $65,000 after purchasing an additional 295 shares during the last quarter. Strs Ohio bought a new stake in shares of Tarsus Pharmaceuticals in the first quarter worth about $288,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Tarsus Pharmaceuticals in the first quarter worth about $26,199,000. Vanguard Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 5.3% in the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock worth $114,380,000 after purchasing an additional 111,433 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of Tarsus Pharmaceuticals by 999.5% during the 1st quarter. Victory Capital Management Inc. now owns 44,320 shares of the company’s stock valued at $2,277,000 after acquiring an additional 40,289 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TARS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research upgraded Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Finally, HC Wainwright increased their target price on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research report on Monday. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $69.33.

Insiders Place Their Bets

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the sale, the chief executive officer directly owned 812,106 shares in the company, valued at $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William J. Phd Link sold 27,116 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. This represents a 15.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,116 shares of company stock valued at $2,177,832. 8.97% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Stock Down 0.5%

NASDAQ TARS opened at $70.82 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. The company has a market capitalization of $2.99 billion, a P/E ratio of -30.39 and a beta of 0.81. Tarsus Pharmaceuticals, Inc. has a one year low of $36.07 and a one year high of $76.81. The stock has a 50 day moving average price of $59.54 and a 200-day moving average price of $49.31.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to the consensus estimate of $95.81 million. Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%. As a group, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.